Association between glycemic control and antidiabetic drugs in type 2 diabetes mellitus patients with cardiovascular complications

Hasniza Zaman Huri^{1,2}
Doris Yew Hui Ling¹
Wan Azman Wan Ahmad^{2,3}

¹Department of Pharmacy, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; ²Clinical Investigation Centre, University Malaya Medical Centre, Lembah Pantai, Kuala Lumpur, Malaysia; ³Cardiology Unit, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia

Purpose: Cardiovascular disease (CVD) is a macrovascular complication in patients with type 2 diabetes mellitus (T2DM). To date, glycemic control profiles of antidiabetic drugs in cardiovascular (CV) complications have not been clearly elucidated. Therefore, this study was conducted retrospectively to assess the association of antidiabetic drugs and glycemic control with CV profiles in T2DM patients. The association of concurrent medications and comorbidities with glycemic control was also investigated.

Methods: A total of 220 T2DM patients from the University of Malaya Medical Centre, Malaysia, who had at least one CV complication and who had been taking at least one antidiabetic drug for at least 3 months, were included. The associations of antidiabetics, cardiovascular diseases, laboratory parameters, concurrent medications, comorbidities, demographics, and clinical characteristics with glycemic control were investigated.

Results: Sulfonylureas in combination ($P=0.002$) and sulfonylurea monotherapy ($P<0.001$) were found to be associated with good glycemic control, whereas insulin in combination ($P=0.051$), and combination biguanides and insulin therapy ($P=0.012$) were found to be associated with poor glycemic control. Stroke ($P=0.044$) was the only type of CVD that seemed to be significantly associated with good glycemic control. Other factors such as benign prostatic hyperplasia ($P=0.026$), elderly patients ($P=0.018$), low-density lipoprotein cholesterol levels ($P=0.021$), and fasting plasma glucose ($P<0.001$) were found to be significantly correlated with good glycemic control.

Conclusion: Individualized treatment in T2DM patients with CVDs can be supported through a better understanding of the association between glycemic control and CV profiles in T2DM patients.

Keywords: glycemic control, antidiabetic drugs, type 2 diabetes mellitus, cardiovascular disease

Introduction

Diabetes mellitus (DM) is a chronic disease and a growing epidemic that has become a global public health concern.¹ Approximately 366 million people worldwide have DM, and this number is expected to increase to 552 million adults by 2030.² According to the National Diabetes Information Clearing house and the World Health Organization, up to 90% of diabetics have type 2 diabetes mellitus (T2DM). The epidemiology of T2DM has risen from 20.8% in 2011 to 22.9% in 2013 among adults 30 years and older in Malaysia.³

T2DM is associated with chronic complications that are subdivided into microvascular and macrovascular complications.⁴ Cardiovascular disease (CVD), which

Correspondence: Hasniza Zaman Huri
Department of Pharmacy, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia
Tel +60 3 7967 6659
Fax +60 3 7967 4964
Email hasnizazh@um.edu.my

is a common macrovascular complication, is a major cause of mortality and morbidity in T2DM patients, representing approximately 50% of all fatalities.⁴ According to the World Heart Federation, people with diabetes are 2–4 times more likely to develop CVDs.⁵

Intensive glycemic control that targets a glycated hemoglobin (A_{1C}) of 7% and below can help to prevent or slow the progression of microvascular complications such as diabetic retinopathy and chronic kidney disease (CKD) in T2DM patients.⁴ In contrast, there is limited information on the association between glycemic control and macrovascular diseases such as CVDs.⁶ The glycemic control profiles of antidiabetic drugs in various cardiovascular complications have not been clearly elucidated.

Although the role of antidiabetic drugs in CVD progression in T2DM patients has not been determined, some studies have shown that some antidiabetic agents cause an improvement in CVD progression in these patients. For example, glucagon-like peptide-1 (GLP-1) receptor agonists can reduce A_{1C} by approximately 1%–1.5% via glucose-dependent secretion of insulin.⁷ Glucose-dependent secretion of insulin can then help to increase glucose use and intensify the metabolic control, which improves myocardial metabolism and myocardial function.⁸ A study showed that a 72-hour infusion with the GLP-1 receptor agonist in human subjects with acute myocardial infarction improved the left ventricular ejection fraction (LVEF).⁹ Sokos et al¹⁰ demonstrated that a 5-week infusion of GLP-1 receptor agonist in both diabetic and chronic heart failure (HF) patients (New York Heart Association [NYHA] class III and IV) significantly improved LVEF in patients with HF.

Metformin is a first-line oral antidiabetic drug used in type 2 diabetes therapy that decreases hepatic glucose production and increases glucose utilization.¹¹ Shah et al¹² found that glycemic control with metformin significantly improved the LVEF in patients with advanced systolic HF (NYHA class III and IV) during a 6-month follow-up. Soraya et al¹³ showed that metformin (25 mg/kg) lowered left ventricular end-diastolic pressure in rats with isoproterenol-induced myocardial infarction. Thus, antidiabetic drugs can be used to improve the clinical parameters of various cardiovascular (CV) complications in T2DM patients.

This study aims to: 1) assess the association between glycemic control, antidiabetic drugs and ischemic heart disease (IHD), acute coronary syndrome (ACS), HF, atrial fibrillation (AF), and/or stroke in T2DM patients; 2) study the association of glycemic control and comorbidities that presented in T2DM patients with IHD, ACS, HF, AF, and/or stroke; and

3) determine the association between glycemic control and concomitant medications taken by T2DM patients with IHD, ACS, HF, AF, and/or stroke. Data obtained from this study may be used to improve the CV profile in T2DM patients by improving glycemic control and the use of antidiabetic agents. The results could enhance our understanding of the association between glycemic control, antidiabetic agents and the profile of CV complications in T2DM patients. This study promotes and supports the concept of pharmaceutical care and individualized treatment in T2DM patients with CV complications.

Material and methods

Study design and setting

This retrospective study was conducted at the University of Malaya Medical Centre (UMMC), Malaysia, a premier teaching hospital in Malaysia with 1,200 beds. The study was conducted in accordance with the Declaration of Helsinki and was approved by the medical ethics committee of the UMMC (reference number 1031.38). The medical ethics committee of the UMMC waived the need for written informed consent from the participants.

Sample population, size, and time frame

The population of this study consisted of T2DM patients at UMMC, who had CV complications and who had been taking at least one antidiabetic drug for at least 3 months.

The sampling time frame for this study was 5 years, from January 1, 2009 to March 31, 2014. The minimum sample size for this study was calculated using the Epi Info Program Version 7.0 (CDC, Atlanta, GA, USA). The level of significance, α , was set at 0.05, and the desired power of the study, $1-\beta$, was 80%. Assuming that the expected proportion of T2DM patients on antidiabetic medications was 22.9% and the confidence limit was 5%, the minimum sample size was 116 patients.

Study population and procedures

The potential patient population included a total of 1,167 patients whose registration numbers were identified using the Hospital Information System, based on the International Statistical Classification of Diseases Tenth Revision (ICD-10) for T2DM (E 11.0–E 11.8). A total of 220 patients fulfilled the inclusion criteria, as shown in Table 1, and they were included in the study.

Data collection forms were used to record patient data. Types of CV complications included in the study were IHD, ACS, HF, AF, and stroke. Patient demographic information

Table 1 Inclusion and exclusion criteria of the study**Inclusion criteria**

- 1) Patients who were diagnosed with T2DM.
- 2) Patients who were diagnosed with at least one cardiovascular complication (IHD, ACS, HF, AF, and/or stroke).
- 3) Patients who were prescribed at least one oral antidiabetic agent and/or insulin.
- 4) Patients who received antidiabetic therapy for at least 3 months.

Exclusion criteria

- 1) Patients who received nonpharmacological therapy/diet.
- 2) Patients who were below 18 years old.

Abbreviations: T2DM, type 2 diabetes mellitus; IHD, ischemic heart disease; ACS, acute coronary syndrome; HF, heart failure; AF, atrial fibrillation.

such as age, sex, ethnicity, height, weight, and body mass index (BMI) was collected. Other patient data such as comorbidity, duration of diabetes, social history (such as smoking and alcohol consumption), laboratory results, medication regimen, and concurrent medications were also collected and reviewed (Table 2).

Statistical analysis

All statistical analyses were performed using the statistical software Statistical Package for Social Science (SPSS), version 20 (IBM SPSS Inc., Chicago, IL, USA). Descriptive statistics such as frequencies, percentages, means, ranges and standard deviations (SD) were used to describe the data. Categorical data were expressed as the absolute number and percentage, whereas continuous data were expressed as the mean $\pm$ SD if normally distributed or as the median (interquartile range) if skewed. The Kolmogorov–Smirnov test or the Shapiro–Wilk test was used to test the normality of continuous data. The Pearson chi-square test with continuity correction was used to examine the association between categorical variables. When the expected cell count was more than 20% or less than 5, the Fisher exact test was used. Cramer's *V* correlation test was used to examine the correlation between two nominal groups, such as antidiabetic regimens and A_{1C} . The Pearson correlation was used to examine the correlation between two continuous data groups, such as low-density lipid and A_{1C} . The significance

level was accepted at $P < 0.05$. The summarized findings are presented in Figure 1.

Results

Demographic characteristics

A total of 1,167 T2DM patients fulfilled the requirement of ICD-10 (E 11.0–E 11.8) from January 1, 2009 to March 31, 2014, and 988 patients were selected through convenient sampling. Of the 520 patients whose medical records were successfully retrieved, 220 fulfilled the inclusion criteria. The study population consisted of slightly more (8.2%) male than female patients. The largest ethnic population in this study was Indian, followed by Malay, Chinese, and others.

As shown in Table 3, the patients' age was normally distributed when tested using the Kolmogorov–Smirnov test, with a mean $\pm$ SD age of 64.7 ± 11.4 years (range, 36–91 years). There were more nonelderly patients (54.1%) than elderly patients (49.5%) in the study.

BMI was available for 94 patients (47.3%). The BMI was normally distributed, with a mean $\pm$ SD of 26.5 ± 4.7 kg/m² (range, 18.20–38.97 kg/m²). Most of the study subjects were obese, followed by preobese, normal range, and underweight.

Clinical characteristics

Most patients with CV complications had had T2DM for more than 20 years (Table 4). A total of 65.9% of patients were nonsmokers. IHD had the highest frequency of CVD types. This was followed by ACS, stroke, HF, and AF. Non-ST-elevation myocardial infarction was the most common type of ACS, followed by unstable angina and ST-elevation myocardial infarction. The NYHA class IV was the most common type of HF, followed by NYHA III, II, and I.

Laboratory parameters

LVEF data were available for 125 patients (Table 5). The data were normally distributed and the mean LVEF was $49.0\% \pm 19.7\%$ (range, 10.0%–85.0%).

Table 2 Definitions used in the study

Terms	Definition
Cardiovascular complications	One of the macrovascular complications that occurred in T2DM patients that involves heart and blood vessels, such as coronary heart disease, cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, congenital heart disease as well as deep vein thrombosis and pulmonary embolism. ⁴
Comorbidities	Diseases or other pathological processes that occur simultaneously with another and require long-term treatment. ⁴²
Good glycemic control	Targeted A_{1C} levels below 8% within 3 months. ⁴
Poor glycemic control	Undesirable A_{1C} levels at 8% and above within 3 months. ⁴

Abbreviations: T2DM, type 2 diabetes mellitus; A_{1C} , glycated hemoglobin.

Figure 1 Overview of methodology.

Abbreviations: UMMC, University of Malaya Medical Centre; T2DM, type 2 diabetes mellitus; ICD-10, International Statistical Classification of Diseases Tenth Revision.

Overall, the majority (56.8%) of patients had achieved the target glycemic control ($A_{1C} < 8.0\%$). A_{1C} was normally distributed, and the mean A_{1C} was $8.1\% \pm 2.0\%$.

Antidiabetic regimens

Figure 2 shows the patients' antidiabetic regimens. Insulin monotherapy was the most commonly used antidiabetic regimen in this study, followed by sulfonylurea monotherapy, and biguanide and sulfonylurea combination therapy.

Figure 3 shows the patients' biguanide regimen. Metformin 500 mg twice daily was the most common dosing

regimen in the biguanide-treated group. This was followed by metformin 850 mg extended-release twice daily and metformin 850/1,700 mg twice daily.

Figure 4 shows the patients' sulfonylurea regimen. For the sulfonylurea-treated group, gliclazide 60 mg modified-release (MR) once daily was used most frequently. This was followed by gliclazide 30 mg MR once daily and gliclazide 120 mg MR once daily.

Figure 5 shows the patients' insulin regimen. For the insulin-treated group, most patients were taking a combination of isophane insulin and soluble insulin subcutaneously.

Table 3 Demographic characteristics of patients (N=220)

Demographic characteristics (N=220)	Number (percentage, %)
Sex	
Male	119 (54.1)
Female	101 (45.9)
Age	
Nonelderly	111 (50.5)
Elderly	109 (49.5)
Ethnicity	
Malay	81 (36.8)
Chinese	55 (25.0)
Indian	83 (37.7)
Other	1 (0.5)
Body mass index (BMI)	
Underweight (<18.5)	2 (0.9)
Normal range (18.5–22.9)	25 (11.4)
Preobese (23.0–27.4)	34 (15.5)
Obese (≥27.5)	42 (19.1)
Unknown	117 (53.2)

Note: BMI classification is based on Clinical Practice Guidelines on Management of Obesity.⁴³

Table 4 Clinical characteristic of patients (N=220)

Clinical characteristics (N=220)	Number (percentage, %)
Duration of T2DM (years)	
<1	3 (1.4)
1–5	17 (7.7)
6–10	36 (16.4)
11–15	29 (13.2)
16–20	18 (8.2)
>20	53 (24.1)
Unknown	64 (29.1)
Smoking status	
Yes	25 (11.4)
No	145 (65.9)
Ex-smoker	38 (17.3)
Unknown	12 (5.5)
Types of CVDs ^a	
IHD	172 (78.2)
ACS	115 (52.3)
NSTEMI	60 (52.7)
STEMI	18 (15.5)
UA	38 (32.8)
HF	29 (13.2)
NYHA I	5 (16.7)
NYHA II	6 (20.0)
NYHA III	8 (26.7)
NYHA IV	11 (36.7)
AF	12 (5.5)
Stroke	49 (22.3)

Note: ^aEach patient may have more than one type of CVD.

Abbreviations: CVDs, cardiovascular diseases; IHD, ischemic heart disease; ACS, acute coronary syndrome; NSTEMI, non-ST-elevation myocardial infarction; STEMI, ST-elevation myocardial infarction; UA, unstable angina; HF, heart failure; NYHA, New York Heart Association; AF, atrial fibrillation; T2DM, type 2 diabetes mellitus.

Table 5 Laboratory parameters

Variables	N	Values
LVEF (%)		
Increased LVEF (>75%)	220	13 (5.9)
Normal LVEF (50%–75%)		53 (24.1)
Moderately reduced (30%–49%)		34 (15.5)
Severely reduced (<30%)		24 (10.9)
Unknown		96 (43.6)
A _{1c} (%)		
<8.0%	220	25 (56.8)
≥8.0%		95 (43.2)
FBG (mmol/L)	195	10.2 (5.0)
Lipid profile		
Total cholesterol (mmol/L)	211	4.4 (1.3)
HDL (mmol/L)	211	1.0 (0.8–1.3)
LDL (mmol/L)	210	2.4 (1.8–3.1)
Triglyceride (mmol/L)	210	1.6 (1.8–3.1)
Blood pressure (BP)		
SBP (mmHg)	142	144 (25.3)
DBP (mmHg)	142	74 (66.8–84.0)
Cardiac biomarker		
CK (U/L)	199	121.0 (76.0–243.0)
CK-MB (U/L)	196	2.0 (1.0–4.0)
TnI (ng/L)	154	0.1 (0.0–0.9)

Notes: Values presented as mean (SD) if normally distributed or median (interquartile range) if skewed for continuous data; n (%) for categorical data.

Abbreviations: LVEF, left ventricular ejection fraction; A_{1c}, glycated hemoglobin; FBG, fasting blood glucose; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure; DBP, diastolic blood pressure; CK, creatine kinase; CK-MB, creatine kinase-MB; TnI, Troponin-I.

This was followed by a subcutaneous (S/C) mixtard and S/C isophane insulin alone.

Figure 6 shows the patients' dipeptidyl peptidase-4 (DPP-4) inhibitor regimen. Sitagliptin 50 mg and Vildagliptin 50 mg were the two most commonly used DPP-4 inhibitors in the DPP-4 inhibitor-treated group.

Figure 7 shows the other antidiabetic agents with their dosing regimens. In this study, only two patients received acarbose 50 mg, one patient received acarbose 100 mg (α -glucosidase inhibitor), one patient received exenatide 10 μ g/40 μ L (glucose-like peptide-1 agonist), and one patient received rosiglitazone 4 mg (thiazolidinedione).

Comorbidities

Figure 8 illustrates the common comorbidities in T2DM patients with CV complications. All patients with comorbidities had multiple comorbidities. Hypertension accounted for the highest percentage among all categories of comorbidities. This was followed by renal disease, hyperlipidemia, obesity, and retinopathy. Figure 9 shows that most patients with renal disease had CKD stage 3 (30–59 mL/min), followed by CKD stages 4 and 5. Only five patients (2.3%) had pneumonia, and ten (4.5%) had hepatic disease. Of the five patients with pneumonia, three had hospital-acquired pneumonia, and two had

Figure 2 Antidiabetic regimens.

Abbreviations: DPP4Is, dipeptidyl peptidase-4 inhibitors; TZDs, thiazolidinediones.

community-acquired pneumonia infections. Fatty liver was the most common hepatic disease, followed by hepatitis and cirrhosis (Figure 10). Other comorbidities included dementia (four cases), hypothyroidism (three), eye cataract (three), urinary tract infection (two), breast cancer (two), chronic obstructive pulmonary disease (one), gastritis (one), cholelithiasis (one), recurrent venous thrombosis (one), peptic ulcer disease (one), pulmonary tuberculosis (one), and osteoporosis (one). Only eleven patients (5%) were without any comorbidity.

Concurrent medications

The pattern of concurrent medication use in T2DM patients with CV complications is summarized in Figure 11. Most patients had received antiplatelet therapy and statins as concurrent medications. Other concurrent medications included

lactulose (two cases), bisacodyl (two), phenytoin (one), morphine (one), L-thyroxine (one), Renifer (vitamin B9 1.5 mg, zinc sulfate 61.8 mg and carbonyl iron 100 mg) (one), phenytoin (one), etoricoxib (one), Berodual metered-dose inhaler (one), Budesonide metered-dose inhaler (one), methyl-dopa (one), unasyn (one), piriton (one), cetirizine (one), motilim (one), duodart (dutasteride and tamsulosin HCl) (one), and gabapentin (one). Supplements included multivitamins, calcitriol, calcium bicarbonate, vitamin B complex, and Ketosteril.

Association between antidiabetic regimens and glycemic control

There was a strong correlation between antidiabetic regimens and the A_{1C} level ($\chi^2=0.33$, $P=0.002$). There was a significant association between glycemic control and insulin use

Figure 3 Dosing regimen of biguanides.

Abbreviations: MTF, metformin; XR, extended release; OD, once daily; BD, twice daily; ON, every night.

Figure 4 Dosing regimen of sulfonylureas.

Abbreviations: OD, once daily; BD, twice daily; MR, modified release; ON, every night.

($\chi^2=20.4$, $df=1$, $P<0.001$) as well as combination sulfonylurea therapy ($\chi^2=9.4$, $df=1$, $P=0.002$; Table 6). In addition, sulfonylurea monotherapy ($\chi^2=14.173$, $df=1$, $P<0.001$) and the combination of biguanides and insulin were significantly associated with glycemic control ($\chi^2=9.8$, $df=1$, $P=0.006$). In this study, sulfonylureas were associated with good glycemic control, whereas insulin was associated with poor glycemic control. The combination of biguanides and insulin was also associated with poor glycemic control.

Association between cardiovascular diseases and glycemic control

The association between CVDs and glycemic control was explored (Table 7). Stroke was the only type of CVD found

to be associated with glycemic control ($\chi^2=4.060$, $df=1$, $P=0.044$). A higher proportion of patients with stroke had good glycemic control.

Association between laboratory parameters and glycemic control

Table 8 shows the correlation between laboratory parameters and glycemic control. There was a significant correlation between low-density lipoprotein (LDL) and glycemic control ($r^2=0.159$, $P=0.021$). The correlation coefficient (r) was +0.159, which indicates a positive, but weak, correlation. Fasting blood glucose was significantly correlated with glycemic control ($r^2=0.418$, $P<0.001$). The correlation coefficient (r) was +0.418, which showed a positive, but weak, correlation.

Figure 5 Dosing regimen of insulin.

Abbreviation: S/C, subcutaneous.

Figure 6 Dosing regimen of DPP-4 inhibitors.

Abbreviation: DPP-4 inhibitors, dipeptidyl peptidase-4 inhibitors.

Association between concurrent medications and glycemic control

The association between concurrent medications and glycemic control (A_{1c}) in T2DM patients with CVDs is presented in Table 9. No concurrent class of drugs was significantly associated with glycemic control.

Association between comorbidities and glycemic control

Benign prostatic hyperplasia (BPH) ($\chi^2=5.485$, $df=1$, $P=0.026$) was the only type of comorbidity that appeared to be significantly associated with glycemic control (Table 10). A higher proportion of patients with BPH had good glycemic control in this study compared to patients who did not obtain good glycemic control.

Association of demographic and clinical characteristics with glycemic control

The association between demographic and clinical characteristics and glycemic control is presented in Table 11. Age ($\chi^2=6.249$, $df=1$, $P=0.018$) was found to be significantly associated with glycemic control. In this study, the elderly group was more likely to have good glycemic control compared with the nonelderly group.

Figure 7 Dosing regimen of other antidiabetic regimens.

Figure 8 Comorbidities in T2DM patients with CVDs.

Note: Each patient may have more than one comorbidity.

Abbreviations: BPH, benign prostatic hyperplasia; CVD, cardiovascular disease; T2DM, type 2 diabetes mellitus.

Discussion

Association between antidiabetic agents and glycemic control

Sulfonylureas

This study found that sulfonylurea use was significantly associated with good glycemic control. Sulfonylureas were the most commonly used antidiabetic agent in this study population; A_{1c} was reduced in these patients by 0.8%–2%, and fasting plasma glucose (FPG) levels were reduced by 60–70 mg/dL.⁷ Sulfonylureas stimulate the release of insulin from β -cells by binding to a specific sulfonylurea receptor on pancreatic β -cells.¹¹

Figure 9 Stage of chronic kidney disease.

Figure 10 Types of liver disease.

In this study, gliclazide modified-release (MR) was the most common drug taken in the sulfonylurea-treated group. A study by Vilar et al¹⁴ showed that gliclazide MR monotherapy significantly improved glycemic control, with a 0.9%–1.8% reduction in A_{1c} . In addition, gliclazide MR was associated with a significantly lower rate of hypoglycemia compared with glimepiride.¹⁵ In the sulfonylurea-treated group in this study, more patients were taking glipizide than

Figure 11 Concurrent medications in T2DM patients with cardiovascular disease.

Note: Each patient may take more than one concurrent medication.

Abbreviations: H2RAs, histamine 2 receptor antagonists; PPIs, proton pump inhibitors; ACEIs, angiotensin converting enzyme inhibitors; ARBs, angiotensin receptor blockers; T2DM, type 2 diabetes mellitus; CCBs, calcium channel blockers.

Table 6 Association between antidiabetic regimens and glycemic control

Antidiabetic regimens	A_{1c} level (n, %)		P-value ^a
	<8.0%	≥8.0%	
Biguanides			
Yes	52 (49.5)	53 (50.5)	P=0.051 ^b
No	73 (63.5)	42 (36.5)	
Sulfonylureas (in combination)			
Yes	72 (60.2)	34 (32.1)	P=0.002 ^{b,*}
No	53 (46.5)	61 (53.5)	
Meglitinides			
Yes	1 (100.0)	0 (0.0)	P=1.000 ^c
No	124 (56.6)	95 (43.4)	
TZDs			
Yes	0 (0.0)	1 (100.0)	P=0.432 ^c
No	125 (57.1)	94 (42.9)	
α-glucosidase inhibitors			
Yes	0 (0.0)	3 (100.0)	P=0.079 ^c
No	125 (57.6)	92 (42.4)	
GLP-1 agonists			
Yes	1 (100.0)	0 (0.0)	P=1.000 ^c
No	124 (56.6)	95 (43.4)	
DPP-4 inhibitors			
Yes	7 (58.3)	5 (41.7)	P=1.000 ^c
No	118 (56.7)	90 (43.3)	
Insulin (in combination)			
Yes	35 (39.8)	53 (60.2)	P<0.001 ^{b,*}
No	90 (68.2)	42 (31.8)	
Biguanides monotherapy			
Yes	19 (55.9)	15 (44.1)	P=1.000 ^b
No	106 (57.0)	80 (43.0)	
Sulfonylureas monotherapy			
Yes	40 (28.4)	10 (21.6)	P<0.001 ^{b,*}
No	85 (50.0)	85 (50.0)	
Insulin monotherapy			
Yes	27 (46.6)	31 (53.4)	P=0.092 ^b
No	98 (60.5)	64 (39.5)	
Biguanides and sulfonylureas			
Yes	25 (62.5)	15 (37.5)	P=0.532 ^b
No	100 (55.6)	80 (44.4)	
Biguanides and insulin			
Yes	6 (28.6)	15 (71.4)	P=0.012 ^{b,*}
No	119 (59.8)	80 (40.2)	
Biguanides, sulfonylureas, and DPP-4 inhibitors			
Yes	2 (40.0)	3 (60.0)	P=0.654 ^c
No	123 (57.2)	92 (42.8)	
Sulfonylureas and insulin			
Yes	1 (50.0)	1 (50.0)	P=1.000 ^c
No	124 (56.9)	94 (43.1)	
Biguanides, sulfonylureas, and insulin			
Yes	0 (0.0)	2 (100.0)	P=0.185 ^c
No	125 (57.3)	93 (42.7)	
Biguanides, sulfonylureas, DPP-4 inhibitors, and insulin			
Yes	1 (100.0)	0 (0.0)	P=1.000 ^c
No	124 (56.6)	95 (43.4)	
DPP-4 inhibitors and insulin			
Yes	1 (100.0)	0 (0.0)	P=1.000 ^c
No	124 (56.6)	95 (43.4)	

(Continued)

Table 6 (Continued)

Antidiabetic regimens	A _{1c} level (n, %)		P-value ^a
	<8.0%	≥8.0%	
Biguanides and DPP-4 inhibitors			
Yes	1 (50.0)	1 (50.0)	P=1.000 ^c
No	124 (56.9)	94 (43.1)	
Biguanides, sulfonylureas, and α-glucosidase inhibitors			
Yes	0 (0.0)	2 (100.0)	P=0.185 ^c
No	125 (57.3)	93 (42.7)	
Sulfonylureas and meglitinides			
Yes	2 (100.0)	0 (0.0)	P=0.507 ^c
No	123 (56.4)	95 (43.6)	
Sulfonylureas and TZDs			
Yes	1 (50.0)	1 (50.0)	P=1.000 ^c
No	124 (56.9)	94 (43.1)	
Sulfonylureas and DPP-4 inhibitors			
Yes	3 (57.1)	3 (42.9)	P=1.000 ^c
No	121 (56.8)	92 (43.2)	

Notes: ^aDegree of freedom = 1; ^bPearson chi-square test with continuity correction; ^cFisher exact test; ^dstatistically significant ($P < 0.05$).

Abbreviations: A_{1c}, glycated hemoglobin; GLP-1 agonists, glucose-like peptide-1 agonists; DPP-4 inhibitors, dipeptidyl peptidase-4 inhibitors; TZDs, thiazolidinediones.

glyburide. Overall, sulfonylureas were associated with good glycemic control, which may help to improve CV profiles in T2DM patients.

Insulin

Insulin and a combination of insulin and biguanides (metformin) were associated with glycemic control. Insulin was found to be associated with poor glycemic control

Table 7 Association between CV complications and glycemic control (A_{1c} level)

CVDs	A _{1c} level (n, %)		P-value ^a
	<8.0%	≥8.0%	
IHD			
Yes	93 (97.7)	79 (45.9)	P=0.164 ^b
No	32 (66.7)	16 (33.3)	
ACS			
Yes	66 (57.4)	49 (42.6)	P=0.892 ^b
No	59 (56.2)	46 (43.8)	
HF			
Yes	17 (58.6)	12 (41.4)	P=0.449 ^c
No	106 (56.1)	83 (43.9)	
AF			
Yes	10 (83.3)	2 (16.7)	P=0.073 ^c
No	115 (55.3)	93 (44.7)	
Stroke			
Yes	34 (69.4)	15 (30.6)	P=0.044 ^{b,*}
No	91 (53.2)	80 (46.8)	

Notes: ^aDegree of freedom = 1; ^bcontinuity correction; ^cFisher exact test; ^dstatistically significant ($P < 0.05$).

Abbreviations: CV, cardiovascular; CVDs, cardiovascular diseases; IHD, ischemic heart disease; ACS, acute coronary syndrome; HF, heart failure; AF, atrial fibrillation; A_{1c}, glycated hemoglobin.

Table 8 Correlation between laboratory parameters and glycemic control

Laboratory parameters	P-value
LVEF	0.155
CK	0.248
CKMB	0.275
Troponin-I	0.084
TG	0.188
LDL	0.021*
HDL	0.835
TC	0.107
SBP	0.773
DBP	0.352
FBG	<0.001*

Note: *Computed using Pearson Correlation and statistically significant ($P < 0.05$).

Abbreviations: LVEF, left ventricular ejection fraction; CK, creatinine kinase; CKMB, creatinine kinase-MB; TG, triglyceride; LDL, low-density lipoprotein; HDL, high-density lipoprotein; TC, total cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose.

Table 9 Association between concurrent medications and glycemic control

Concurrent medications	A _{1c} level (n, %)		P-value ^a
	<8.0%	≥8.0%	
ACEI			
Yes	51 (54.8)	42 (45.2)	P=0.712 ^b
No	74 (58.3)	53 (41.7)	
ARB			
Yes	16 (50.0)	16 (50.0)	P=0.516 ^b
No	109 (58.0)	79 (42.0)	
β-blocker			
Yes	64 (61.5)	40 (38.5)	P=0.229 ^b
No	61 (52.6)	55 (47.4)	
CCB			
Yes	61 (59.2)	42 (40.8)	P=0.590 ^b
No	64 (54.7)	53 (45.3)	
Diuretics			
Yes	45 (52.9)	40 (47.1)	P=0.462 ^b
No	79 (59.0)	55 (41.0)	
Nitrate			
Yes	31 (55.4)	25 (44.6)	P=0.921 ^b
No	94 (57.3)	70 (42.7)	
Fibrate			
Yes	8 (47.1)	9 (52.9)	P=0.398 ^b
No	117 (58.2)	85 (42.3)	
Statin			
Yes	100 (57.1)	75 (42.9)	P=0.982 ^b
No	25 (55.6)	20 (44.4)	
α-receptor blocker			
Yes	11 (61.1)	7 (38.9)	P=0.892 ^b
No	114 (56.4)	88 (43.6)	
Anticoagulants			
Yes	8 (57.1)	6 (42.9)	P=1.000 ^b
No	117 (56.8)	89 (44.6)	
Antiplatelets			
Yes	103 (55.4)	12 (35.3)	P=0.411 ^b
No	22 (64.7)	12 (35.3)	

(Continued)

Table 9 (Continued)

Concurrent medications	A _{1c} level (n, %)		P-value ^a
	<8.0%	≥8.0%	
Hematinic agents			
Yes	25 (61.4)	14 (35.9)	P=0.404 ^b
No	100 (55.2)	81 (44.8)	
Supplements			
Yes	21 (63.6)	12 (36.4)	P=0.505 ^b
No	104 (55.6)	83 (44.4)	
Gout preparations			
Yes	7 (87.5)	1 (12.5)	P=0.142 ^c
No	118 (55.7)	94 (44.3)	
H2RA			
Yes	15 (71.4)	6 (28.6)	P=0.242 ^b
No	110 (55.6)	89 (44.9)	
PPI			
Yes	34 (66.7)	17 (33.3)	P=0.145 ^b
No	91 (53.8)	78 (46.2)	
Antidepressants			
Yes	3 (50.0%)	3 (50.0)	P=1.000 ^c
No	121 (56.8)	92 (43.2)	

Notes: ^aDegree of freedom =1; ^bPearson chi-square test with continuity correction; ^cFisher exact test.

Abbreviations: ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; H2RA, histamine 2 receptor antagonist; PPI, proton pump inhibitor; A_{1c}, glycated hemoglobin.

Table 10 Association between comorbidities and glycemic control

Comorbidities	A _{1c} level (n, %)		P-value ^a
	<8.0%	≥8.0%	
Renal disease			
Yes	59 (62.1)	36 (37.9)	P=0.214
No	66 (52.8)	59 (47.2)	
Hepatic disease			
Yes	3 (30.0)	7 (70.0)	P=0.105 ^b
No	22 (58.1)	88 (41.9)	
Retinopathy			
Yes	13 (50.0)	13 (50.0)	P=0.592 ^b
No	112 (57.7)	82 (42.3)	
BPH			
Yes	10 (90.9)	1 (9.1)	P=0.026 ^{b,*}
No	115 (55.0)	94 (45.0)	
Hyperlipidemia			
Yes	52 (57.8)	38 (42.2)	P=0.920 ^c
No	73 (56.2)	57 (43.8)	
Obesity			
Yes	22 (55.0)	18 (45.0)	P=0.861 ^c
No	103 (57.2)	77 (42.8)	
Pneumonia			
Yes	5 (100.0)	0 (0.0)	P=0.071 ^b
No	120 (55.8)	95 (44.2)	
Anemia			
Yes	8 (72.7)	3 (27.3)	P=0.358 ^b
No	117 (56.0)	92 (44.0)	
Hypertension			
Yes	98 (59.0)	68 (41.0)	P=0.314 ^c
No	27 (50.0)	27 (50.0)	

Notes: ^aDegree of freedom =1; ^bFisher exact test; ^cPearson chi-square test with continuity correction; ^{*}statistically significant (P<0.05).

Abbreviations: A_{1c}, glycated hemoglobin; BPH, benign prostatic hyperplasia.

Table 11 Association between demographic and clinical characteristics and glycemic control

Clinical and demographic characteristics	A _{1c} level (n, %)		P-value
	<8.0%	≥8.0%	
Sex			
Male	66 (55.5)	53 (44.5)	P=0.761 ^a
Female	59 (58.4)	42 (41.6)	
Age			
Nonelderly	54 (48.6)	57 (51.4)	P=0.018 ^{a,*}
Elderly	70 (65.4)	37 (34.6)	
Ethnicity			
Malay	45 (54.9)	37 (45.1)	P=0.344 ^b
Chinese	36 (65.5)	19 (34.5)	
Indian	43 (52.4)	39 (47.6)	
Other	1 (100.0)	0 (0.0)	
BMI			
Underweight (<18.5)	1 (50.0)	1 (50.0)	P=0.958 ^b
Normal weight (18.5–22.9)	15 (60.0)	10 (40.0)	
Preobese (23.0–27.4)	19 (55.9)	15 (44.1)	
Obese (≥27.5)	22 (52.4)	20 (47.6)	
Unknown	68 (58.1)	49 (41.9)	
Smoking status			
Yes	12 (48.0)	13 (52.0)	P=0.207 ^b
No	80 (55.2)	65 (44.8)	
Ex-smoker	23 (60.5)	15 (39.5)	
Unknown	10 (83.3)	2 (16.7)	
Duration of T2DM (years)			
<1	1 (33.3)	2 (66.7)	P=0.185 ^b
1–5	10 (58.8)	7 (41.2)	
6–10	27 (75.0)	9 (25.0)	
11–15	15 (51.7)	14 (48.3)	
16–20	9 (50.0)	9 (50.0)	
>20	25 (47.2)	28 (52.8)	
Unknown	38 (59.4)	26 (40.6)	

Notes: ^aPearson chi-square test with continuity correction; ^bFisher exact test; ^{*}statistically significant (P<0.05).

Abbreviation: A_{1c}, glycated hemoglobin; T2DM, type 2 diabetes mellitus; BMI, body mass index.

in this study. This is consistent with Adham et al¹⁶ who showed that patients treated with insulin or a combination of insulin and hypoglycemic agents had poor glycemic control. This may be because patients treated with insulin or a combination of insulin and other oral antidiabetic agents had more severe comorbid illnesses and uncontrolled diabetes, and thus required more aggressive treatment to control their illnesses.¹⁶

In addition, hypoglycemic effect, weight gain, and the anabolic effect of insulin also contributed to the poor glycemic control associated with insulin.¹⁶ Insulin is associated with an increased risk of hypoglycemic effects. A study by Parsaik et al¹⁷ showed that insulin contributed to the highest percentage of hypoglycemia cases requiring ambulance services. Weight gain is another common problem related to the use of insulin because of counteracting hypoglycemic

complications and changing adiposity regulators.¹⁸ However, a study by Meneghini et al¹⁹ revealed that insulin detemir improved glycemic control with less hypoglycemic risk and no weight gain in T2DM patients. In this study, the combination of subcutaneous isophane insulin and soluble insulin was the most common type of insulin regimen received by patients. A study by Choi et al²⁰ revealed that long-term continuous subcutaneous insulin infusion therapy in T2DM patients was associated with optimal glycemic control and an improvement in β -cell function.

Association between cardiovascular complications and glycemic control

In this study, stroke was the only CV complication found to be associated with glycemic control; no significant association was found between glycemic control and IHD, ACS, HF, and AF. Studies by Kauffman et al¹⁸ and Penno et al⁶ showed that glycemic control was not associated with CV complications. This finding was in contrast to the United Kingdom Prospective Diabetes Study (UKPDS) in which intensive glycemic control had a significantly positive effect on patients with CVD after a 10-year follow-up.²¹ The Heart Outcome Prevention Evaluation (HOPE) study also reported a contradictory finding, in which the glycemic level was significantly associated with incident CV complications.²² This difference could be because of the small sample size ($n=220$ patients) recruited in this study and the short duration of follow-up compared with the UKPDS trial and HOPE study. Thus, additional research is needed to determine a definitive association between glycemic control and CVDs.

Stroke

Stroke was found to be significantly associated with good glycemic control in this study. This finding was in contrast to the study conducted by Ray et al²³ which reported that glycemic control (targeted FPG less than 6 mmol/L) had no significant effect on stroke or all-cause mortality. A systemic review conducted by Bellolio et al²⁴ concluded that glycemic control by intravenous insulin administration in acute ischemic stroke did not significantly affect functional outcome, final neurological deficit, or death. The discrepancy may be due to some potential biases in the review process in the study by Bellolio et al²⁴ which may cause inaccurate interpretation of results. For example, a moderate number of studies (eleven trials) were included in the analysis, and there were a small number of subjects in each study.²⁴ A study by Baird et al²⁵ revealed that infarcts

expanded more in diabetic patients than in nondiabetic patients, which indicates that hyperglycemia was associated with a change in infarct volume. However, there was no evidence showing that a reversal in hyperglycemia could improve the prognosis in stroke.²⁶ Because the association between glycemic control and stroke is still not clearly elucidated, further investigation is needed.

Association between laboratory parameters and glycemic control

LDL cholesterol

This study found a significant, positive correlation between A_{1C} and elevated LDL cholesterol. This result is consistent with a study conducted by Adham et al¹⁶ which revealed that LDL cholesterol was significantly associated with glycemic control. Dyslipidemia is a common comorbidity in T2DM patients with CV complications, and LDL cholesterol is the therapeutic target for dyslipidemia treatment, which may affect glycemic control.²⁷ However, our results did not clarify whether lipid control and glycemic control were related because the majority of patients were already on lipid-lowering regimens, such as statins and fibrates. Some studies also showed that statins can affect glycemic control in T2DM patients.^{28,29} For example, a study by Nakata et al²⁸ showed that atorvastatin treatment significantly increased A_{1C} but not FPG in diabetic patients. This was because it impaired glucose metabolism on account of insulin resistance and decreased SLC2A4 expression in white adipose tissue. This showed that atorvastatin could potentially affect glycemic control. Thus, the elevated LDL cholesterol level often adds an additional burden to patient conditions and complicates their therapies.

Association between comorbidities and glycemic control

Benign prostatic hyperplasia

There was a significant association between BPH and glycemic control in this study. There was a higher percentage of males compared with females in this study, which may explain the significant association between BPH and glycemic control. Elderly patients with BPH have a higher prevalence of CVDs than the general population,³⁰ because BPH may be related to higher blood pressure, IHD, or other CV pathologic conditions. However, the underlying mechanisms are unclear, and further studies are needed to identify whether BPH is related to CVD.³⁰ A study by Sarma et al³¹ demonstrated that there was no significant association between glycemic control and BPH characteristics such as

prostate growth and prostate-specific antigen level in T2DM patients with BPH. A study by Shionoiri et al³² showed that doxazosin, which is a BPH medication, improved glucose intolerance by significantly reducing A_{1C} . In addition, a study by Derosa et al³³ showed the synergistic effects of doxazosin and acarbose, an α -glucosidase inhibitor that improves glycemic control, in patients with impaired glucose tolerance. Further research is needed to determine the relationship between BPH and glycemic control.

Association between concurrent medications and glycemic control

Statins

In this study, statins were not significantly associated with glycemic control. This was consistent with Zhou et al³⁴ who reported that statin therapy did not significantly affect glycemic control in patients with T2DM. However, the same study showed that atorvastatin had a detrimental effect on A_{1C} in subgroup analysis. A study by Simsek et al³⁵ also reported the same results, ie, that high-dose atorvastatin (atorvastatin 80 mg) reduced glycemic control. In this study, less than 10% of patients received atorvastatin, which could be why the result was not significant. The majority of these patients (65.5%) received simvastatin because it had a better effect on A_{1C} compared with atorvastatin.³⁴ Thus, statin therapy did not affect glycemic control in this study.

Antiplatelet therapy

No significant association was found between antiplatelet therapy and glycemic control. Approximately 45% of patients were taking aspirin, and 23% were taking aspirin together with clopidogrel. A study by Singh et al³⁶ reported that different doses of aspirin had no significant effect on inflammation, oxidative stress, insulin resistance, or endothelial function in T2DM. Thus, aspirin, which has a cardioprotective effect, did not affect glycemic control in T2DM.

Diuretics

Diuretics were not significantly associated with glycemic control. This contrasts with a study by Blackburn and Wilson,³⁷ who showed that thiazide diuretics were associated with adverse effects on glycemic control because they decreased insulin sensitivity, resulting in increased hepatic glucose production. However, this effect was less apparent with a lower dose of thiazide (12.5–25 mg of hydrochlorothiazide) in this study, and, therefore, the result was not significant. In the diuretic-treated group, the majority of patients received furosemide (61.2%), and

its effect on glycemic control was not significant. Thus, there was no significant association between diuretics and glycemic control.

Association between demographic and clinical characteristics with glycemic control

Age

In this study, elderly patients were associated with good glycemic control, and nonelderly patients were associated with poor glycemic control. This finding was consistent with several studies, which reported that a younger age was associated with worse glycemic control.^{16,38} In this study, there was a higher percentage of nonelderly patients than elderly patients. The younger group of patients may be less motivated to manage their diabetic condition, because they may be busy with their job and have less time to comply with a healthy lifestyle, medication, and clinic visits. Effective education and behavior medication programs should be aimed at the younger population because this group of patients may have a longer life expectancy, and it is important to prevent complications associated with diabetes.³⁸

Duration of diabetes

The duration of diabetes in this study was not associated with glycemic control. In contrast to this finding, Ji et al³⁹ reported that glycemic control was related to the duration of T2DM. This finding was consistent with Chan et al⁴⁰ who showed that glycemic control was positively correlated with diabetes duration. When duration of T2DM increased, the number of oral antidiabetic agents also increased, and insulin therapy intensified.⁴¹

Study strength

This study has several strengths. First, in this cross-sectional and retrospective study, all factors such as antidiabetic agents and glycemic control (exposure), CV profile (outcome) and comorbidities and concurrent medications (confounders) were measured. Data were also collected on the whole study population at a single time to examine the association between antidiabetic agents and glycemic control with CV complications. Specific types of CV complications were included such as IHD, ACS, AF, HF, and stroke, which represent most of the Malaysian population. In this study, the duration of antidiabetic agents was at least 3 months, and exposure to these agents was well defined. In addition, A_{1C} values for each patient were collected and recorded, which made the association between glycemic control and CV complications more reliable.

Study limitations

The retrospective nature of the study design caused the whole data collection process to be based solely on information available from patients' medical records. Dependence on medical records tends to introduce bias and produce inaccurate results, especially in circumstances where there are missing data on patients' information that is relevant to the study. Important information might also be neglected or deliberately omitted due to illegible handwriting. Patients' adherence to antidiabetic medications also cannot be assessed unless adherence status is recorded in the case notes.

Conclusion

Sulfonylureas in combination, insulin in combination, sulfonylurea monotherapy, and insulin and metformin combination therapy were associated with glycemic control in this population. Overall, the antidiabetic regimen was strongly correlated with glycemic control. Stroke was the only type of CV complication found to be associated with glycemic control. BPH was the only comorbidity that appeared to be significantly associated with glycemic control. No concurrent medication was found to be significantly associated with glycemic control. Other factors like LDL cholesterol level and age were correlated with glycemic control. The identification of underlying factors associated with glycemic control may help in preventing CV progression in T2DM patients. Thus, additional care is required for patients with multiple risk factors.

Acknowledgment

The authors thank the University of Malaya, Malaysia (RP024B-14HTM), for financial and technical support.

Disclosure

The authors report no conflicts of interest in this work.

References

- Hu FB. Globalization of diabetes: the role of diet, lifestyle, and genes. *Diabetes Care*. 2011;34(6):1249–1257.
- International Diabetes Federation. *Diabetes Atlas*. 5th ed. Brussels, Belgium: IDF; 2011.
- Wan Nazaimoon WM, Md Isa SH, Wan Mohamad WB, et al. Prevalence of diabetes in Malaysia and usefulness of HbA1C as a diagnostic criterion. *Diabet Med*. 2013;30(7):825–828.
- American Diabetes Association. Standards of Medical Care in Diabetes. *Diabetes Care*. 2014;36:S14–S87.
- World Heart Federation. *Cardiovascular Disease Risk Factors: Diabetes*. Geneva, Switzerland: World Heart Federation; 2014. Available from: <http://www.world-heart-federation.org/cardiovascular-health/cardiovascular-disease-risk-factors/diabetes/>. Accessed March 26, 2014.
- Penno G, Solini A, Zoppini G, et al. Hemoglobin A1C variability as an independent correlate of cardiovascular disease in patients with type 2 diabetes: a cross-sectional analysis of the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. *Cardiovasc Diabetol*. 2013;12:98.
- Dipiro JT, Talbert RL, Yee GC, et al. *Pharmacotherapy: A Pathophysiologic Approach*. 8th ed. New York, NY: McGraw-Hill Medical; 2011.
- Thrainsdottir I, Malmberg K, Olsson A, Gutniak M, Ryden L. Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure. *Diab Vasc Dis Res*. 2004;1(1):40–43.
- Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. *Circulation*. 2004;109(8):962–965.
- Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. *J Cardiac Fail*. 2006;12(9):694–699.
- Fowler MJ. Diabetes treatment part 2: oral agents for glycemic management. *Clin Diabetes*. 2007;25(4):131–134.
- Shah DD, Fonarow GC, Horwich TB. Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes. *J Cardiac Fail*. 2010;16(3):200–206.
- Soraya H, Khorrami A, Garjani A, Maleki-Dizaji N, Garjani A. Acute treatment with metformin improves cardiac function following isoproterenol induced infarction in rats. *Pharmacol Rep*. 2012; 64:1476–1484.
- Vilar L, Canadas V, Arruda MJ, et al. Comparison of metformin, gliclazide MR and rosiglitazone in monotherapy and in combination for type 2 diabetes. *Arq Bras Endocrinol Metabol*. 2010;54(3):311–318.
- Scherthaner G, Grimaldi A, Di Mario U, et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. *Eur J Clin Invest*. 2004;34(8):535–542.
- Adham M, Froelicher ES, Batieha A, Ajlouni K. Glycaemic control and its associated factors in type 2 diabetic patients in Amman, Jordan. *East Mediterr Health J*. 2010;16(7):732–739.
- Parsaik AK, Carter RE, Myers LA, Basu A, Kudva YC. Hypoglycemia requiring ambulance services in patients with type 2 diabetes is associated with increased long term mortality. *Endocr Pract*. 2013;19(1):29–35.
- Kauffman AB, Delate T, Olson KL, et al. Relationship between haemoglobin A1C values and recurrent cardiac events. *Clin Drug Investig*. 2008;28(8):501–507.
- Meneghini LF, Rosenberg KH, Koenen C, Merilainen MJ, Luddeke HJ. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. *Diabetes Obes Metab*. 2007;9(3):418–427.
- Choi SB, Lee JH, Kim S, et al. Improvement of β -cell function after achievement of optimal glycaemic control via long-term continuous subcutaneous insulin infusion therapy in non-newly diagnosed type 2 diabetic patients with suboptimal glycaemic control. *Diabetes Metab Res Rev*. 2013;29(6):473–482.
- UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet*. 1998;352(9131):854–865.
- Gerstein HC, Pogue J, Mann JF, et al. The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. *Diabetologia*. 2005;48(9):1749–1755.
- Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. *Lancet*. 2009;373(9677):1765–1772.

24. Bellolio MF, Gilmore RM, Stead LG. Insulin for glycaemic control in acute ischaemic stroke. *Cochrane Database Syst Rev*. 2011; 9:CD005346.
25. Baird TA, Parsons MW, Phan T, et al. Persistent poststroke hyperglycemia is independently associated with infarct expansion and worse clinical outcome. *Stroke*. 2003;34:2208–2214.
26. Lindsberg PJ, Roine RO. Hyperglycemia in acute stroke. *Stroke*. 2004;35(2):363–364.
27. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). *Eur Heart J*. 2011;32(14):1769–1818.
28. Nakata M, Nagasaka S, Kusaka I, et al. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. *Diabetologia*. 2006;49(8):1881–1892.
29. Sukhija R, Prayaga S, Marashdeh M, et al. Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients. *J Invest Med*. 2009;57(3):495–499.
30. Karatas OF, Bayrak O, Cimentepe E, Unal D. An insidious risk factor for cardiovascular disease: benign prostatic hyperplasia. *Int J Cardiol*. 2010;144(3):452.
31. Sarma AV, St Sauver JL, Hollingsworth JM, et al. Diabetes treatment and progression of benign prostatic hyperplasia in community-dwelling black and white men. *Urology*. 2012;79(1):102–108.
32. Shionoiri H, Ashino K, Yamanaka K, et al. Effect of doxazosin therapy on glucose tolerance and lipid metabolism in hypertensive patients with impaired glucose tolerance. *Clin Ther*. 1997;19(3):527–536.
33. Derosa G, Cicero AF, D'Angelo A, et al. Synergistic effect of doxazosin and acarbose in improving metabolic control in patients with impaired glucose tolerance. *Clin Drug Investig*. 2006;26(9):529–539.
34. Zhou Y, Yuan Y, Cai RR, et al. Statin therapy on glycaemic control in type 2 diabetes: a meta-analysis. *Expert Opin Pharmacother*. 2013; 14(12):1575–1584.
35. Simsek S, Schalkwijk CG, Wolffenbuttel BH. Effects of rosuvastatin and atorvastatin on glycaemic control in type 2 diabetes – the CORALL study. *Diabet Med*. 2012;29(5):628–631.
36. Singh K, Raghavan VA. *Insulin Resistance and Atherosclerosis in Lipoproteins in Diabetes Mellitus*. New York, NY: Springer; 2014: 41–44.
37. Blackburn DF, Wilson TW. Antihypertensive medications and blood sugar: theories and implications. *Can J Cardiol*. 2006;22(3): 229–233.
38. Quah JH, Liu YP, Luo N, How CH, Tay EG. Younger adult type 2 diabetic patients have poorer glycaemic control: a cross-sectional study in a primary care setting in Singapore. *BMC Endocr Disord*. 2013;13(1):18.
39. Ji LN, Lu JM, Guo XH, et al. Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables. *BMC Pub Health*. 2013;13(1):602.
40. Chan WB, Chan JC, Chow CC, et al. Glycaemic control in type 2 diabetes: the impact of body weight, β -cell function and patient education. *Oxford J Med*. 2000;93(3):183–190.
41. Huri HZ, Selamat S, Vethakkan SR. Factors associated with utilization of dipeptidyl-4 inhibitors in patients with type 2 diabetes mellitus: a cross-sectional retrospective study. *Int J Endocrinol*. 2014;2014:367564. Available from: <http://dx.doi.org/10.1155/2014/367564>. Accessed July 16, 2015.
42. Barber N, Parsons J, Clifford S, Darracott R, Home R. Patients' problems with new medication for chronic conditions. *Quality and Safety in Health Care*. 2004;13(3):172–175.
43. Ministry of Health. (2004). Clinical practice guidelines on management of obesity.

Drug Design, Development and Therapy

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which

Submit your manuscript here: <http://www.dovepress.com/drug-design-development-and-therapy-journal>

has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Dovepress